A phase III trial of albumin-bound paclitaxel versus docetaxel as first-line therapy in patients with metastatic breast cancer.

Trial Profile

A phase III trial of albumin-bound paclitaxel versus docetaxel as first-line therapy in patients with metastatic breast cancer.

Planning
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2008

At a glance

  • Drugs Docetaxel; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Apr 2008 Agreement reached with FDA with regard to endpoints, under a Special Protocol Assessment.
    • 01 Apr 2008 The trial is expected to be initiated in the second half of 2008.
    • 13 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top